Diagnosing and treating Alzheimer's disease
Described herein are methods, systems and compositions for the diagnosis, prognosis and treatment of dementia and Alzheimer's disease. Also described are methods, systems and compositions to distinguish between Alzheimer's disease and Parkinson's disease. In various embodiments levels of PACAP and/or SIRT3 are analyzed for the diagnosis, prognosis and treatment of dementia and Alzheimer's disease.
1. A method of detecting PACAP and SIRT3 protein expression in a human subject suspected of having late onset Alzheimer's disease (LOAD), the method comprising the steps of:
obtaining a sample from the human subject suspected of having LOAD;
detecting an expression level of PACAP protein in the sample; and
detecting an expression level of SIRT3 protein in the sample.
2. The method of claim 1 , wherein the sample comprises at least one of a brain tissue or cerebrospinal fluid.
3. The method of claim 1 , wherein the expression level of PACAP protein in the sample is detected using at least one of ELISA, Western blot, and flow cytometry.
4. The method of claim 1 , wherein the detecting the expression level of PACAP protein and detecting the level of SIRT3 protein in the sample comprises using antibody-based assays.
5. The method of claim 1 and further comprising comparing the detected expression level of PACAP protein in the subject's sample to a reference level of PACAP protein.
6. The method of claim 5 and further comprising administering a composition comprising PACAP to the subject if the subject's expression level of PACAP is below that of the reference level of PACAP protein.
7. A method of detecting PACAP and SIRT3_protein expression in a human subject suspected of having at least one of late onset Alzheimer's disease (LOAD), Parkinson's disease with Dementia (PDD), and Frontotemporal Lobe Dementia (FTLD), the method comprising the steps of:
obtaining a sample from the human subject suspected of having at least one of LOAD, PDD, and FTLD;
detecting an expression level of PACAP protein in the sample; and
detecting an expression level of SIRT3 protein in the sample.
8. The method of claim 7 , wherein the sample comprises at least one of brain tissue and cerebrospinal fluid.
9. The method of claim 7 and further comprising administering a composition comprising PACAP to the human subject.
10. The method of claim 7 , wherein the expression level of PACAP protein in the sample is detected using at least one of ELISA, Western blot, and flow cytometry.
11. The method of claim 7 and further comprising comparing the detected expression level of PACAP protein in the subject's sample to a reference level of PACAP protein.
12. The method of claim 11 , wherein human subjects with LOAD exhibit reduced levels of PACAP expression compared to human subjects with PDD and FTLD.